XBI - SPDRÂ S&P Biotech ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
99.08
+0.02 (+0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close99.06
Open99.37
Bid0.00 x 1100
Ask0.00 x 800
Day's Range98.10 - 99.54
52 Week Range74.25 - 101.55
Volume3,781,118
Avg. Volume4,760,606
Net Assets5.19B
NAV95.68
PE Ratio (TTM)N/A
Yield0.25%
YTD Return11.62%
Beta (3y)1.86
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Trending: Technology Sector Surges to Record Highs Despite Trade Jitters
    ETF Database3 days ago

    Trending: Technology Sector Surges to Record Highs Despite Trade Jitters

    Investors have bought into the technology sector with fervor as markets enjoyed a brief period of tranquility just before politicians resumed their belligerent rhetoric.

  • ETF Trends5 days ago

    Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend

    Biotechnology sector-related exchange traded funds were among the few areas of the markets that shook off the tariffs-talk volatility and was still in the green Tuesday as Sarepta Therapeutics (SRPT) surged on positive preliminary results from its experimental treatment. The BioShares Biotechnology Products Fund (BBP) , which follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, and SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space, were among the better performing ETFs Tuesday, rising 2.2% and 1.3%, respectively. Meanwhile, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, was 1.3% higher Tuesday.

  • Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
    Investor's Business Daily9 days ago

    Biotech Funds Tacked On $76 Million This Week — Are They Recovering?

    Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.

  • Investopedia10 days ago

    Why Biotech Stocks May Reach New Highs

    Biotech stocks are nearing a big break out as measured by the SPDR S&P Biotech ETF ( XBI). The group is already having a strong start to 2018, quietly outpacing not only the S&P 500 but the most talked about sectors in the market, technology ( XLK) and consumer stocks ( XLY). The biotech ETF is sitting right below a significant resistance level at $97.90, the previous all-time high for the ETF, and should that price rise above technical resistance, it would mark a big breakout.

  • Biotech Sector Continue to Dazzle Despite Market Distress
    Market Realist19 days ago

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.

  • CNBC20 days ago

    Cramer: Pharmaceutical stocks are underperforming 'like nothing I've ever seen'

    CNBC's Jim Cramer says that he is disappointed by the recent performance of pharmaceutical stocks, saying there should be far more deals in the health-care space. Cramer says despite pharma's underperformance, he likes biotech stocks, which have been making a bit of a comeback this year. CNBC's Jim Cramer said Monday that he is disappointed by the recent performance of pharmaceutical stocks, saying there should be far more deals in the health-care space.

  • Benzinga24 days ago

    Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act

    President Donald Trump is keeping pharmaceutical execs, lobbyists and investors on their toes. “[The notice] is consistent with his administration's ‘bully pulpit’ strategy of cajoling the drug makers into industry-led changes to drug pricing,” Height analyst Andrea Harris said in a note.

  • Barrons.com24 days ago

    Will Big Data Lead to Big Biotech Returns?

    Big Data could improve results in the biopharmaceutical industry—if companies can improve their use and avoid pitfalls, writes Jefferies' Michael Yee in a report issued today. The proper implementation of new data and analytics tools could "accelerate the probability of success" in the drug industry and boost process efficiencies, driving billions in cost savings, according to Yee. In this way, using Big Data to "find better drugs at a lower cost" will put drug makers at an advantage by increasing return on investment. Companies that are using Big Data include Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Eli Lilly (LLY), Merck (MRK), Novartis (NVS), and Regeneron Pharmaceuticals (REGN).

  • Benzinga25 days ago

    'Right To Try' Law Signed By Trump Increases Patient Access To Experimental Drugs

    Under the new law, terminally ill patients who are ineligible for clinical trials and have exhausted all treatment options will now be allowed to test experimental therapies not yet approved by the FDA. In providing a workaround for the FDA’s long and arduous trial processes, the law accelerates the time it takes for patients to access a new formula and may make it easier for clinical-stage pharmaceuticals developing orphan drugs to test their products.

  • Biotech ETFs Are the Best Way to Play the Recovering Sector
    InvestorPlace25 days ago

    Biotech ETFs Are the Best Way to Play the Recovering Sector

    The summer of 2015 marked the end of the glory years in the biotechnology sector. The biotech valuation correction that lasted over two years may be coming to an end. Some well-known, large-cap names — such as AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) — are currently trading at forward P/E multiples in the 10+ range.

  • A Look at Incyte’s Valuation as of May 25
    Market Realist26 days ago

    A Look at Incyte’s Valuation as of May 25

    Incyte Corporation (INCY) is a biopharmaceutical company with headquarters in Wilmington, Delaware. Incyte’s business includes the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.

  • Investopedialast month

    Biotech Stocks Could Lead Summer Rally

    Biotech stocks turned higher on May 11 after President Trump outlined a series of steps the administration might take to control skyrocketing drug prices. The lack of details triggered a relief rally underpinned by skepticism that the initiatives will pass Congress and their deep reliance on industry contributions.

  • Analyzing Ionis’s Q1 Revenue Streams
    Market Realistlast month

    Analyzing Ionis’s Q1 Revenue Streams

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.

  • MarketWatchlast month

    President Trump’s big drug price speech boosts pharma stocks

    After weeks of build-up, drug industry watchers began to have real concerns about President Donald Trump’s big drug price speech on Friday. Many of the changes that were mentioned on Friday had been raised before by his administration, including drug price negotiation for certain government programs. Other proposals seemed unlikely to significantly bring down drug prices in the near-term, which Trump described as a goal of the plan.

  • ETF Trendslast month

    6 Top Healthcare ETFs Rally as Trump Vows End to ‘Global Freeloading’

    Healthcare stocks and top healthcare ETFs rallied Friday after President Donald Trump vowed to end to "global freeloading" that has allowed foreign countries to pay less on American-manufactured medicines. The Health Care Select Sector SPDR (XLV), the largest healthcare exchange traded fund, gained 1.5% Friday while the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, rose 2.7% and VanEck Vectors Generic Drugs ETF (GNRX) , which focuses on generic drug producers, added 2.2%.

  • Investopedia2 months ago

    Biotech Stocks Face a Steep Drop

    An analysis of Biotech ETF XBI's chart suggests the sector could be set for a decline of over 8%.

  • ETF Database2 months ago

    Trending: Investors Apathetic to Barclays' $1.2 Billion ETN Shutoff

    This week, investors were preoccupied with Russia, as the country’s equities fell dramatically after the relations with countries in the West, including the U.S., deteriorated. First in the list, however, is Barclays Capital, as the asset management arm of the British bank said it would shut down a host of exchange-traded notes (ETNs). Russia is second in the list followed by crude oil, which has been on a tear lately thanks to dropping stockpiles in the U.S. Leveraged ETFs and biotechnology stocks close the list. Check our previous trends edition at Trending: Soybean Prices Whipsaw on Trade War Fears.

  • Why These Small Cap Biotech ETFs are Soaring
    Zacks2 months ago

    Why These Small Cap Biotech ETFs are Soaring

    These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

  • Barrons.com2 months ago

    Could Big Biotech Earnings Be a Bust?

    Singh's more conservative on Gilead Sciences (GILD), writing that its HIV drug Biktarvy is seeing a good launch, but not as strong Genvoya, and Regeneron Pharmaceuticals (REGN), where he sees a strong second half in terms of regulatory approvals as balanced by "burgeoning operating expenses and negative sentiment." He has Perform ratings on both stocks. Moving down the line, he's more bullish on mid- and small-cap biotechs, which are not only benefitting from M&A in the sector, but should also "continue to positively diverge from large-cap biotech" in first-quarter earnings results as well.

  • Barrons.com2 months ago

    Tech, Biotech Rife With Buys, M&A, Disruptive Trends

    Tom Vandeventer, portfolio manager of the Tocqueville Opportunity Fund (TOPPX), which is up nearly 10% so far this year, thinks that trend will continue. Tech and biotech are two major themes running through the fund’s portfolio, which Vandeventer told Barron’s is indicative of the fact that “there are a lot of disruptive technologies that are coming to fruition” in both sectors. The fund focuses more on small- and mid-cap stocks, meaning that M&A is a theme throughout his holdings, in both tech and biotech, bolstered by industry trends (the move to the cloud, the rise of gene-editing therapies, respectively), as well the fact that larger players are flush with cash—thanks to lower corporate taxes and repatriated capital—to facilitate acquisitions.

  • Barrons.com2 months ago

    Better Days Ahead for Big Biotechs

    The first quarter is traditionally not a strong one for biotech earnings for a host of reasons—including fewer shipping days, inventory reductions after year-end price increases, weather disruptions, and annual copay resets in many health insurance plans. The SPDR S&P Biotech ETF (XBI) is up 2.8% to $91.38 today, and the iShares Nasdaq Biotechnology ETF (IBB) is climbing 2.2% to $107.55.

  • Barrons.com2 months ago

    Bigger Biotechs Bound for Earnings Bounty

    Just as Barron's predicted, this year has seen smaller biotech stocks outperform their larger peers, with the SPDR S&P Biotech ETF (XBI) up 15% year-to-date, while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 1.2%.  Now, as we gear up for first-quarter earnings in the sector, SunTrust Robinson Humphrey sees a number of potentially better-than-expected results ahead. The team, led by analyst Yatin Suneja, writes that investors appear "poised to reward companies with good financial performance." He believes that positive pricing trends, along with tailwinds from foreign exchange and moderate expectations on the Street can drive outperformance, even if seasonality is a headwind. Suneja thinks that among big biotechs, Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceuticals (BMRN), Celgene (CELG), Exelixis (EXEL), Regeneron Pharmaceuticals (REGN), and Sarepta Therapeutics (SRPT) have the best chance of reporting better-than-expected sales in the quarter, while he sees a more in-line quarters for Biogen (BIIB) and Incyte (INCY).

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist2 months ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Novartis Enters Agreement to Acquire AveXis
    Market Realist2 months ago

    Novartis Enters Agreement to Acquire AveXis

    On April 9, 2018, Novartis AG (NVS) announced that it had entered into an agreement to acquire AveXis (AVXS), a clinical-stage gene therapy company, for ~$8.7 billion. 

  • ETF Trends2 months ago

    Catalysts Abound for Biotech ETFs

    Biotechnology stocks and biotech ETFs tumbled in the back half of March and to start April. For example, the SPDR S&P Biotech ETF (NYSEArca: XBI) came into Monday with a loss of almost 12.6% over the past ...